Starten Sie Ihre Suche...


Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen

Integration of Trastuzumab with or without Pertuzumab into the perioperative chemotherapy in HER2-positive gastric cancer: the Innovation study

Laufzeit: 01.01.2015 - 31.12.2022

Kurzfassung


This is a randomized phase II study with internal control. The randomization takes place in the ratio 1:2:2 (control: Experimental Group 1: Experimental Group 2). Potentially appropriate patients are being examined centrally with regard to their HER2 status. After confirmation of the HER2-positive disease, the participating patients are centrally randomized with the EORTC system of randomization. A minimization technique is used for the random assignment to the three treatment groups. The...This is a randomized phase II study with internal control. The randomization takes place in the ratio 1:2:2 (control: Experimental Group 1: Experimental Group 2). Potentially appropriate patients are being examined centrally with regard to their HER2 status.  After confirmation of the HER2-positive disease, the participating patients are centrally randomized with the EORTC system of randomization. A minimization technique is used for the random assignment to the three treatment groups. The layering (stratification) is done according to histological subtype (intestinal/non-intestinal); Korea versus Europe; Tumor localisation in gastro-esophageal transition (GET) versus residual stomach (non-GET) and HER2 IHC 3 + versus IHC2 +/fish +.
 
» weiterlesen» einklappen

Beteiligte Einrichtungen